论文部分内容阅读
自八十年代以来,国外在“透皮控释给药”(TTS)一类的剂型研究工作方面进展十分迅速。首先研制成功TTS药剂的是美国的ALZO公司,瑞士一些著名大公司(如汽巴—嘉基)在这方面也不甘落后。据统计美国和西欧先后上市的TTS型药物已有十几种之多。通过皮肤给药确有不少优点。首先是使用极为方便,因为众所周知皮肤是人体最大的器官。药物经由皮肤进入全身血液循环便于发挥药物的治疗作用,避免了肝脏首过效应的影响而且决不会产生常规给药出现的血药浓度峰谷现象。此外,透皮给药对胃肠道无刺激作用,还可减少给药次数和总剂量。
Since the 1980s, foreign countries have made rapid progress in the formulation of dosage forms such as transdermal controlled release (TTS). First, the successful development of TTS pharmaceutical is the United States ALZO company, some of the famous Swiss companies (such as Ciba - Gaby) is not far behind in this regard. According to statistics, the United States and Western Europe have listed TTS drugs have been as many as a dozen. There are many advantages to being delivered through the skin. The first is extremely easy to use because it is well known that the skin is the largest organ in the body. Drugs through the skin into the systemic blood circulation to facilitate the drug’s therapeutic effect, to avoid the effects of the first pass of the liver and will never produce the peak drug concentration peak valley phenomenon. In addition, transdermal administration does not stimulate the gastrointestinal tract, but also reduce the number of administration and total dose.